Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

OBJECTIVE: The aim of this study was to evaluate the cost-effectiveness of gefitinib plus chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations in China. METHODS: A decision-analytic Markov model was...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Yamin, Zhang, Qilin, He, Xucheng, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572736/
https://www.ncbi.nlm.nih.gov/pubmed/34764692
http://dx.doi.org/10.2147/CMAR.S334643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572736/
https://www.ncbi.nlm.nih.gov/pubmed/34764692
http://dx.doi.org/10.2147/CMAR.S334643

Ejemplares similares